Cargando…
Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
PURPOSE: To estimate the number of sick leave days and productivity costs in active workers with osteoarthritis (OA) who initiated opioid treatment for moderate/severe chronic pain in clinical practice in Spain. PATIENTS AND METHODS: This is a secondary analysis of the longitudinal, retrospective OP...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8937618/ https://www.ncbi.nlm.nih.gov/pubmed/35321217 http://dx.doi.org/10.2147/OARRR.S346746 |
_version_ | 1784672382751866880 |
---|---|
author | Sicras-Mainar, Antoni Tornero-Tornero, Juan Carlos Vargas-Negrín, Francisco Lizarraga, Isabel Sicras-Navarro, Aram Rejas-Gutierrez, Javier |
author_facet | Sicras-Mainar, Antoni Tornero-Tornero, Juan Carlos Vargas-Negrín, Francisco Lizarraga, Isabel Sicras-Navarro, Aram Rejas-Gutierrez, Javier |
author_sort | Sicras-Mainar, Antoni |
collection | PubMed |
description | PURPOSE: To estimate the number of sick leave days and productivity costs in active workers with osteoarthritis (OA) who initiated opioid treatment for moderate/severe chronic pain in clinical practice in Spain. PATIENTS AND METHODS: This is a secondary analysis of the longitudinal, retrospective OPIOIDS study, using electronic medical records (EMR) of patients aged ≥18 years, who started an opioid treatment for moderate/severe chronic OA pain between 2010 and 2015 after treatment failure with ≥1 first-line drugs (acetaminophen, metamizole and/or nonsteroidal anti-inflammatory drugs [NSAIDs]). The number of days of sick leave and productivity costs were analyzed during a follow-up period of 36 months. RESULTS: A total of 5089 patients with moderate/severe chronic OA pain, aged 56.8 years (standard deviation [SD]: 4.6) (56.6% were female), were analyzed: 73.3% of them started a treatment with weak opioids and 26.7% of them were treated with strong opioids. At 36 months, adherence was 21.0% (strong opioids: 15.4%; weak opioids: 23.0%; p<0.001), and 77% of patients had at least one sick leave related with chronic OA pain, with an average of 93 days off work in all working patients (120.5 days in patients with sick leaves). Besides, 16.9% of the study population had sick leave periods that lasted at least 6 months. Pain reduction was modest (−1.2 points; −4.0%, p<0.001). The cost of sick leave was €2594 patient/year, and factors such as older age (β=0.043), female sex (β=0.036), comorbidities (β=0.035) and strong opioid use (β=0.031) were associated with higher productivity costs (p<0.05 in all associations). CONCLUSION: Active workers who started opioid treatment for moderate/severe chronic OA pain showed an increased frequency of sick leave and productivity cost, with a modest effect on pain relief. Older age, female sex, comorbidities, and strong opioids were associated with higher costs for society. |
format | Online Article Text |
id | pubmed-8937618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-89376182022-03-22 Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study Sicras-Mainar, Antoni Tornero-Tornero, Juan Carlos Vargas-Negrín, Francisco Lizarraga, Isabel Sicras-Navarro, Aram Rejas-Gutierrez, Javier Open Access Rheumatol Original Research PURPOSE: To estimate the number of sick leave days and productivity costs in active workers with osteoarthritis (OA) who initiated opioid treatment for moderate/severe chronic pain in clinical practice in Spain. PATIENTS AND METHODS: This is a secondary analysis of the longitudinal, retrospective OPIOIDS study, using electronic medical records (EMR) of patients aged ≥18 years, who started an opioid treatment for moderate/severe chronic OA pain between 2010 and 2015 after treatment failure with ≥1 first-line drugs (acetaminophen, metamizole and/or nonsteroidal anti-inflammatory drugs [NSAIDs]). The number of days of sick leave and productivity costs were analyzed during a follow-up period of 36 months. RESULTS: A total of 5089 patients with moderate/severe chronic OA pain, aged 56.8 years (standard deviation [SD]: 4.6) (56.6% were female), were analyzed: 73.3% of them started a treatment with weak opioids and 26.7% of them were treated with strong opioids. At 36 months, adherence was 21.0% (strong opioids: 15.4%; weak opioids: 23.0%; p<0.001), and 77% of patients had at least one sick leave related with chronic OA pain, with an average of 93 days off work in all working patients (120.5 days in patients with sick leaves). Besides, 16.9% of the study population had sick leave periods that lasted at least 6 months. Pain reduction was modest (−1.2 points; −4.0%, p<0.001). The cost of sick leave was €2594 patient/year, and factors such as older age (β=0.043), female sex (β=0.036), comorbidities (β=0.035) and strong opioid use (β=0.031) were associated with higher productivity costs (p<0.05 in all associations). CONCLUSION: Active workers who started opioid treatment for moderate/severe chronic OA pain showed an increased frequency of sick leave and productivity cost, with a modest effect on pain relief. Older age, female sex, comorbidities, and strong opioids were associated with higher costs for society. Dove 2022-03-15 /pmc/articles/PMC8937618/ /pubmed/35321217 http://dx.doi.org/10.2147/OARRR.S346746 Text en © 2022 Sicras-Mainar et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sicras-Mainar, Antoni Tornero-Tornero, Juan Carlos Vargas-Negrín, Francisco Lizarraga, Isabel Sicras-Navarro, Aram Rejas-Gutierrez, Javier Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study |
title | Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study |
title_full | Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study |
title_fullStr | Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study |
title_full_unstemmed | Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study |
title_short | Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study |
title_sort | sick leave and costs in active workers with chronic osteoarthritis pain in spain: outcomes of the opioids real world study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8937618/ https://www.ncbi.nlm.nih.gov/pubmed/35321217 http://dx.doi.org/10.2147/OARRR.S346746 |
work_keys_str_mv | AT sicrasmainarantoni sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy AT tornerotornerojuancarlos sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy AT vargasnegrinfrancisco sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy AT lizarragaisabel sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy AT sicrasnavarroaram sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy AT rejasgutierrezjavier sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy |